[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 23.23.50.247. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
March 3, 2004

High-Intensity Statin Treatment for Coronary Heart Disease

Author Affiliations

Author Affiliation: Harvard School of Public Health and Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.

JAMA. 2004;291(9):1132-1134. doi:10.1001/jama.291.9.1132

In this issue of THE JOURNAL, Nissen and colleagues1 report the findings of the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) study, a clinical trial comparing the effects of 2 statins, pravastatin (40-mg dose) and atorvastatin (80-mg dose). The REVERSAL study is a first in 2 respects. First, it showed that a statin regimen using the most efficacious drug (atorvastatin) and dose available for lowering low-density lipoprotein cholesterol (LDL-C) when the trial began improved coronary atherosclerosis more than pravastatin, which represented a statin regimen that had been fully established to safely reduce cardiovascular disease and mortality.26 Second, the advantage of atorvastatin was demonstrated using an intravascular ultrasound examination of the coronary arteries, a technique that quantifies plaque by visualizing the coronary arterial intima. While this study is an important achievement, it is equally important to determine what it adds to current knowledge of lipid therapy in atherosclerotic cardiovascular disease and how it should affect clinical practice.

First Page Preview View Large
First page PDF preview
First page PDF preview
×